Equities

Charles River Laboratories International Inc

Charles River Laboratories International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)194.19
  • Today's Change6.29 / 3.35%
  • Shares traded502.26k
  • 1 Year change+1.01%
  • Beta1.3720
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform3
Hold14
Sell1
Strong Sell1

Share price forecast in USD

The 17 analysts offering 12 month price targets for Charles River Lbrtrs ntrntl Inc have a median target of 220.00, with a high estimate of 259.21 and a low estimate of 151.00. The median estimate represents a 13.29% increase from the last price of 194.19.
High33.5%259.21
Med13.3%220.00
Low-22.2%151.00

Earnings history & estimates in USD

On Nov 06, 2024, Charles River Lbrtrs ntrntl Inc reported 3rd quarter 2024 earnings of 2.59 per share. This result exceeded the 2.43 consensus of the 15 analysts covering the company and under-performed last year's 3rd quarter results by 4.78%.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate-0.36%
Charles River Lbrtrs ntrntl Inc reported annual 2023 earnings of 10.67 per share on Feb 14, 2024.
Average growth rate+12.86%
More ▼

Revenue history & estimates in USD

Charles River Laboratories International, Inc. had 3rd quarter 2024 revenues of 1.01bn. This bettered the 976.02m consensus of the 13 analysts covering the company. This was 1.91% below the prior year's 3rd quarter results.
Average growth rate-0.41%
Charles River Laboratories International, Inc. had revenues for the full year 2023 of 4.13bn. This was 3.86% above the prior year's results.
Average growth rate+12.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.